Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on myocardial energy metabolism in HFpEF with type 2 diabetes
ChiCTR2200059645Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: NT-proBNP and Epicardial adipose tissue volume. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200059645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059645.